MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH ...

Experts discourage regular consumption of energy drinks. High caffeine content paired with the supplemental ingredients in ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

The secret to a healthier and “younger” heart lies in the vagus nerve. A recent study coordinated by the Sant'Anna School of Advanced Studies in Pisa and published in Science Translational ...

US drug developer Cytokinetics today announced that Myqorzo (aficamten) is now available for prescription in 5mg, 10mg, 15mg ...

If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

China NMPA approves Sanofi’s Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome: Paris Saturday, January 17, 2026, 11:00 Hrs ...

AHA scientific statement provides a framework for standardizing baseline and provocative invasive hemodynamic protocols in HF ...

CareMed ®, an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO™ (aficamten), indicated for the treatment of adults with symptomatic obstructive ...

In August 2025, Sanofi acquired the rights to develop and commercialize Redemplo in Greater China from Visirna Therapeutics, a majority-owned subsidiary of Arrowhead Pharmaceuticals.

Iron is essential for oxygen transport and energy metabolism, yet both deficiency and excess are linked to cardiovascular risk. The National Library of Medicine shows that higher heme iron intake ...

Many people turn to energy drinks on tough days when regular coffee falls short. Late nights from work, studying, or family ...